Menu
Scancell
Scancell's mission is to develop products that stimulate the immune system to treat or prevent cancer.
Drug discovery – cancer
School of Medicine
Profile
Scancell’s mission is to develop products that stimulate the immune system to treat or prevent cancer.
In December 2006, Scancell sold its pipeline of direct killing monoclonal antibodies to Arana Therapeutics, an Australian biopharmaceutical company. The deal allowed Scancell to focus its efforts entirely on its innovative ImmunoBody® and Moditope® cancer vaccine programmes.
Scancell’s first clinical candidate drug, ImmunoBody® is a DNA vaccine which is being developed for the treatment of melanoma.
Scancell began trading on AIM in 2008.
News and press releases
@scancellpharma on Twitter
$SCLP Encouraging early efficacy data from monotherapy part of ModiFY Phase 1/2 clinical trial https://tinyurl.com/vbjx9ejj $SCNLF $SCP #SCLP #SCNLF #SCP
$SCLP Scancell Holdings hails early 'very encouraging' results from phase I/II cancer trial https://tinyurl.com/2h87t6eh @scancellpharma $SCNLF #SCLP #SCNLF
Pleased to share the latest Outlook report from Trinity Delta focussing on Scancell’s antibody and vaccine oncology platforms.
https://www.scancell.co.uk/Data/Sites/1/media/fininfo/sclp-outlook-230215.pdf
We are pleased to have been awarded an Indian patent for our Moditope® programme based on exploiting stress-induced post-translational modifications (siPTMs) such as citrullination to develop novel anti-cancer vaccines.
Scancell Holdings plc - Scancell announces positive response in COVIDITY trial
https://scancell.co.uk/Data/Sites/1/media/publications/rns/scancell-announces-positive-response-in-covidity-trial_final_13.02.23.pdf
We are thrilled to welcome Dr Jean-Michel Cosséry to Scancell as Non-Executive Chairman of the Board.
https://www.scancell.co.uk/Data/Sites/1/media/publications/rns/scancell-appoints-dr-jean-michel-coss%C3%A9ry-as-non-executive-chairman-of-the-board-01.02.23-final.pdf
$SCLP Scancell announces appointment of Dr Jean-Michel Cosséry as its non-executive chairman with immediate effect https://tinyurl.com/29g3omwc @scancellpharma $SCNLF #SCLP #SCNLF
We are pleased to have been awarded a Singaporean patent on our anti-glycan monoclonal antibody with specificity for the sialyl-di-Lewisᵃ glycan expressed on glycoproteins